# Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

> **NCT06463743** · PHASE2 · RECRUITING · sponsor: **State University of New York at Buffalo** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06463743
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-24
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463743, "Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06463743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*